Covid-19: Remdesivir is recommended for authorisation by European Medicines AgencyBMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m2610 (Published 29 June 2020) Cite this as: BMJ 2020;369:m2610
- Jacqui Wise
The antiviral drug remdesivir is the first medicine against covid-19 to be recommended for authorisation in the European Union.
The European Medicines Agency’s (EMA) human medicines committee has granted a conditional marketing authorisation for remdesivir to treat covid-19 in adults and adolescents from age 12 with pneumonia who require supplemental oxygen.1 The authorisation allows a drug to be sold for a year in the EU before all necessary data on its efficacy and side effects are available.
Since May remdesivir has been made available in the UK to selected NHS patients in hospital …